CytRx Corp. (CYTR)

1.68
0.04 2.40
NASDAQ : Health Technology
Prev Close 1.64
Open 1.63
Day Low/High 1.63 / 1.69
52 Wk Low/High 1.43 / 5.99
Volume 57.48K
Avg Volume 384.20K
Exchange NASDAQ
Shares Outstanding 28.04M
Market Cap 45.42M
EPS -1.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

CytRx Announces Key Addition To Corporate Development Team

CytRx Announces Key Addition To Corporate Development Team

Company Engages Expert Advisor Eric L. Curtis to Lead Internal Development Efforts and Manage External Partner Relationships

CytRx Announces The Presentation Of New LADR™ Candidate Data At The American Association For Cancer Research 2018 Annual Meeting

CytRx Announces The Presentation Of New LADR™ Candidate Data At The American Association For Cancer Research 2018 Annual Meeting

All Three Studies Submitted Were Selected for Poster Presentations

CytRx Corporation Regains Nasdaq Listing Compliance

CytRx Corporation Regains Nasdaq Listing Compliance

Hires Investigation Firm to Initiate Short Selling Audit

CytRx Corporation Highlights Recent Progress At Freiburg, Germany, Laboratory And Provides Update For Oncology Pipeline

CytRx Corporation Highlights Recent Progress At Freiburg, Germany, Laboratory And Provides Update For Oncology Pipeline

Company's Goal is to Create a New Class of Rationally Designed, Breakthrough Anti-Cancer Drugs

CytRx Corporation Announces Reverse Stock Split

CytRx Corporation Announces Reverse Stock Split

Shares of Common Stock Will Begin Trading on a Post-Split Basis on November 1, 2017

Interesting CYTR Call Options For March 2018

Interesting CYTR Call Options For March 2018

Investors in CytRx Corp saw new options begin trading today, for the March 2018 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 235 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Goodbye CytRx, Your Game Is Over

Goodbye CytRx, Your Game Is Over

Hope springs eternal, until it's dashed on the rocks and buried at sea.

For These Small-Cap Biotech CEOs, Stock Promotion, Not Drug Development, Was Priority No. 1

For These Small-Cap Biotech CEOs, Stock Promotion, Not Drug Development, Was Priority No. 1

An SEC enforcement action uncovers the deep involvement and brazen misbehavior of biotech CEOs in an illegal stock promotion scheme.

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The firms all have drugs they want the feds to bend the rules to approve.

Could These 9 Drugs Gain FDA Approval in the Age of Trump?

Could These 9 Drugs Gain FDA Approval in the Age of Trump?

Nine biotech and drug companies want FDA approval, but need changed standards to get it.

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The firms all have drugs they want the feds to bend the rules to approve.

First Week of CYTR September 15th Options Trading

First Week of CYTR September 15th Options Trading

Investors in CytRx Corp saw new options begin trading this week, for the September 15th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 233 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

TheStreet's biotech columnist offers his own report card on biotech stocks.

CytRx CEO Pockets Millions of Dollars as Failed Sarcoma Drug Moves to FDA

CytRx CEO Pockets Millions of Dollars as Failed Sarcoma Drug Moves to FDA

CytRx announced a plan Tuesday to seek U.S. marketing approval of aldoxorubicin based more on hocus-pocus than credible study results.

Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive

Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive

The imbalances in patient baseline characteristics provided an assist to Corbus' resunab treatment response and undermines the credibility of the trial results, a source says.

24-Hour Deadline Alert: Law Offices Of Howard G. Smith Reminds Investors Of The Upcoming September 23rd Deadline In The Class Action Lawsuit Against CytRx Corporation

24-Hour Deadline Alert: Law Offices Of Howard G. Smith Reminds Investors Of The Upcoming September 23rd Deadline In The Class Action Lawsuit Against CytRx Corporation

Law Offices of Howard G. Smith reminds investors of the upcoming  September 23, 2016 deadline to file a lead plaintiff motion in the class action lawsuit filed on behalf of investors who purchased or otherwise...

TheStreet Quant Rating: D- (Sell)